Korean J Clin Oncol.  2025 Apr;21(1):13-19. 10.14216/kjco.24317.

Tumor budding in invasive breast carcinoma and its association with clinicopathological parameters: an experience from a tertiary care center in India

• Shah A
• Malik S
• Khan AA
• Ahluwalia C

• KMID: 2567632
• DOI: http://doi.org/10.14216/kjco.24317

Abstract

Purpose
Breast cancer is one of the most common cancers globally, with an increasing incidence rate. It is a heterogeneous disease, and early metastasis remains a challenge. Tumor budding, defined as single tumor cells or small clusters at the invasive front, has been suggested as a prognostic marker in various cancers, including breast cancer. This study aims to evaluate tumor budding in invasive breast carcinoma using the International Tumor Budding Consensus Conference (ITBCC) scoring system and explore its association with pathological characteristics and prognosis.
Methods
A retrospective study was conducted on 100 mastectomy specimens of histopathologically confirmed invasive breast carcinoma, excluding cases that underwent chemotherapy or radiotherapy. Tumor budding was classified as low, intermediate, or high based on the ITBCC scoring method, and associations with clinicopathological features were analyzed using appropriate statistical tests.
Results
Tumor budding was classified as high in 52% of cases. A significant association was found between high tumor budding and higher tumor grade (P<0.001), negative estrogen receptor and progesterone receptor status (P<0.001), positive HER2neu status (P=0.003), and high Ki-67 levels (P<0.001). High tumor budding was also linked to higher T stage, and dermal lymphovascular invasion (P=0.001). Our findings support previous studies showing that high tumor budding is associated with poor prognostic factors such as higher tumor grade, negative hormone receptor status, and higher T stage.
Conclusion
Tumor budding is a potential prognostic marker in breast cancer, associated with more aggressive tumor characteristics.

Keyword

Breast carcinoma; Biomarkers; Ductal; Lymphatic metastasis; Tumor budding